2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma

EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report

Pdf Summary

The document outlines a medical case of a patient with EIMS (epithelioid inflammatory myofibroblastic sarcoma), a rare and aggressive cancer. Initially diagnosed in December 2018 following a right upper lobectomy, histology confirmed the presence of EIMS with ALK expression.<br /><br />By March 2020, the disease had progressed to the brain, with persistent headaches and double vision indicating metastasis. A significant metastatic tumor was found in the right frontoparietal region, requiring surgical removal and subsequent anticonvulsant and corticosteroid therapy.<br /><br />In May 2020, further disease progression was noted, with multiple brain lesions detected in follow-up CT scans. The patient was considered for external radiotherapy, which commenced as they awaited approval for Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor (ALK-TKI) treatment. Targeted therapy with alectinib began in June 2020, allowing for the discontinuation of radiotherapy.<br /><br />In May 2021, a new tumor was discovered and surgically excised, which was diagnosed as a fibrous meningioma. Further disease progression occurred by June 2023, accompanied by another seizure and a CT scan revealing a high tumor in the right frontal region, necessitating additional neurosurgery.<br /><br />Overall, the patient's treatment course highlights the complexities in managing EIMS, with challenges arising from tumor recurrence and metastasis, necessitating a combination of surgical, radiotherapeutic, and targeted therapies.

Asset Subtitle

Michal Urda

Meta Tag

Speaker Michal Urda

Topic Mesothelioma, Thymoma, and Other Thoracic Tumors

Keywords

EIMS

epithelioid inflammatory myofibroblastic sarcoma

ALK expression

brain metastasis

surgical removal

anticonvulsant therapy

corticosteroid therapy

ALK-TKI treatment

alectinib

tumor recurrence